Zobrazeno 1 - 5
of 5
pro vyhledávání: '"IDEAL Study Group"'
Autor:
Guido Schäfer, Christian Hoffmann, Keikawus Arasteh, Dirk Schürmann, Christoph Stephan, Björn Jensen, Matthias Stoll, Johannes R. Bogner, Gerd Faetkenheuer, Jürgen Rockstroh, Hartwig Klinker, Georg Härter, Albrecht Stöhr, Olaf Degen, Eric Freiwald, Anja Hüfner, Sabine Jordan, Julian Schulze zur Wiesch, Marylyn Addo, Ansgar W. Lohse, Jan van Lunzen, Stefan Schmiedel, the IDEAL study group
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-8 (2019)
Abstract Background To evaluate clinical outcomes after either immediate or deferred initiation of antiretroviral therapy in HIV-1-infected patients, presenting late with pneumocystis pneumonia (PCP) or toxoplasma encephalitis (TE). Methods Phase IV,
Externí odkaz:
https://doaj.org/article/82290680ddf94e3c96d93f441f9081ba
Autor:
Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-De Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Group, TEAM Study Group
Publikováno v:
European Journal of Cancer, 95, 59-67
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
Background Extended endocrine therapy beyond 5 years for postmenopausal breast cancer has been studied within multiple phase III trials. Treatment compliance in these trials is generally poor. In this analysis, we aimed to determine factors that were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d486b65ea2eb3d71c07edc8efa8a0b64
https://hdl.handle.net/1887/95506
https://hdl.handle.net/1887/95506
Autor:
Blok, Erik J., Kroep, Judith R., Meershoek-Klein Kranenbarg, Elma, Duijm-de Carpentier, Marjolijn, Putter, Hein, Liefers, Gerrit-Jan, Nortier, Johan W. R., Rutgers, Emiel J. Th., Seynaeve, Caroline M., van de Velde, Cornelis J. H., On Behalf of the IDEAL Study Group
Publikováno v:
Breast Cancer Research & Treatment; Apr2018, Vol. 168 Issue 2, p413-420, 8p
Autor:
Pedersen, T. R., Færgeman, Ole, Kastelein, J. J., Olsson, A. G., Tikkanen, M. J., Holme, I., Larsen, Mogens Lytken, Bendiksen, F. S., Lindahl, C., Szarek, M., Tsai, J., Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Publikováno v:
Pedersen, T R, Færgeman, O, Kastelein, J J, Olsson, A G, Tikkanen, M J, Holme, I, Larsen, M L, Bendiksen, F S, Lindahl, C, Szarek, M, Tsai, J & Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group 2005, ' High-dose atorvastatin vs usual simvastatin for secondary prevention after myocardial infarction: the IDEAL study: A randomized controlled trial ', JAMA: The Journal of the American Medical Association, vol. 294, no. 19, pp. 2437-45 .
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pure_au_____::5cfd7e0ee3af2d03f250fe96d279af65
https://pure.au.dk/portal/da/publications/highdose-atorvastatin-vs-usual-simvastatin-for-secondary-prevention-after-myocardial-infarction-the-ideal-study-a-randomized-controlled-trial(43fb3720-be4c-11da-bee9-02004c4f4f50).html
https://pure.au.dk/portal/da/publications/highdose-atorvastatin-vs-usual-simvastatin-for-secondary-prevention-after-myocardial-infarction-the-ideal-study-a-randomized-controlled-trial(43fb3720-be4c-11da-bee9-02004c4f4f50).html
Autor:
Kastelein JJP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM, TNT Study Group, IDEAL Study Group
Publikováno v:
Circulation; 6/10/2008, Vol. 117 Issue 23, p3002-3009, 8p